Immunocore Holdings (IMCR) Receivables (2019 - 2026)

Immunocore Holdings has reported Receivables for 8 years, with the latest figure at $81.1 million in Q1 2026.

• Quarterly Receivables rose 28.53% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 28.53% YoY) and the FY2025 annual result came in at $74.0 million, up 17.44% from the prior year.
• Receivables grew to $81.1 million in Q1 2026 per IMCR's latest filing, from $74.0 million in the prior quarter.
• Over five years, Receivables peaked at $81.1 million in Q1 2026 and troughed at $52.1 million in Q4 2023.
• A 5-year average of $65.2 million and a median of $63.7 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables jumped 183.78% in 2022, then slipped 18.35% in 2023.
• Over 5 years, Receivables stood at $63.8 million in 2022, then retreated by 18.35% to $52.1 million in 2023, then advanced by 20.95% to $63.0 million in 2024, then climbed by 17.44% to $74.0 million in 2025, then advanced by 9.59% to $81.1 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $81.1 million, $74.0 million, and $75.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.